Securities code: 688276 Securities abbreviation: Baike Biotechnology Announcement No.: 2025-015

Changchun Baike Biotechnology Co., Ltd

Announcement on the postponement of some fundraising projects

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was held on April 17, 2025

The fifth meeting of the sixth board of directors and the second meeting of the sixth board of supervisors deliberated and passed the "Proposal on the Postponement of Some Fund-raising Projects", and agreed that the company would extend the time for the "annual output of 6 million adsorbed acellular diphtheria-pertussis (three-component) combined vaccine project" (hereinafter referred to as the "diphtheria-pertussis project") to reach the scheduled usable state. The sponsor, CITIC Securities Co., Ltd., issued a clear verification opinion. This matter does not need to be submitted to the shareholders' meeting of the company for deliberation. The relevant information is hereby announced as follows:

First, the basic situation of the funds raised

With the approval of the China Securities Regulatory Commission's "Reply on Agreeing to the Registration of Changchun Baike Biotechnology Co., Ltd.'s Initial Public Offering of Shares" (Zheng Jian Xu Xu [2021] No. 1594), the company issued 41,284,070 RMB ordinary shares (A shares) by way of public issuance to the public, at an issue price of RMB 36.35 per share, raising a total of RMB 1,500,675,944.50, deducting underwriting fees, sponsor fees, audit fees, lawyer fees, information disclosure and other issuance costs After RMB104,881,526.35, the actual net amount of funds raised was RMB1,395,794,418.15. The above-mentioned funds in place have been verified by Daxin Certified Public Accountants (Special General Partnership), and Daxin Yanzi [2021] No. 7-00002 "Changchun Baike Biotechnology Co., Ltd. Capital Verification Report" has been issued. The company has adopted a special account storage management for the raised funds.

2. Use of raised funds

As of December 31, 2024, the Company's proceeds were used as follows:

Amount unit: RMB 10,000 yuan

It is planned to use the fund-raising cumulative investment project project to reach the pre-plan

Project Name Amount of Funds Raised Progress Determination of Availability

Aggregate date

1. Changchun Baike Biotechnology

The joint-stock company has an annual output of 20 million

Live attenuated varicella vaccine for human population, 14,351.66 12,620.67 Closed August 2023

Live attenuated herpes zoster vaccine

eye

2. Changchun Baike Biotechnology

The joint-stock company has an annual output of 6 million people

Adsorbed acellular diphtheria-pertussis 22,021.92 22,173.62 in August 2025

(three-component) combination vaccine item

eye

3. Changchun Baike Biotechnology

Annual output of joint-stock company 10 million 6,336.44 4,573.29 Closed March 2024

Human nasal spray of live attenuated influenza

Seedlings (liquid preparations) project

4. Changchun Baike Biotechnology

The annual output of the joint-stock company is 3 million 18,243.15 18,243.15 in progress December 2026

Lyophilized human rabies vaccine

(Human diploid cells) project

5. R&D projects under research 79,189.42 54,266.39 In progress /

Total 140,142.59 111,877.13 / /

Note: If there is a difference in the mantissa between the sum of the partial totals and the direct addition of the additives in the above table, it is due to rounding.

3. The specific situation and reasons for the postponement of the diphtheria-pertussis project

(1) The specific circumstances of the postponement of the diphtheria-pertussis project

The dates on which the diphtheria-tetanus-pertussis project reaches its intended usable state are adjusted as follows:

The previous item of this adjustment The project after this adjustment

Project Name Item Reach Appointment Reach Appointment Reach Appointment Use

Use Status Date Status Date

Changchun Baike Biotechnology Co., Ltd. has an annual output of 600

10,000 adsorbed cell-free diphtheria-pertussis (three components) August 2025 April 2028

Combination Vaccine Project

(2) The reasons for the postponement of the diphtheria-pertussis project

Although the company's diphtheria-tetanus-tetanus-tetanus-tetanus-

According to the company's accounting policy, the construction project in progress is based on the construction of the asset to reach the intended usable state

If the final accounts have not yet been completed, the cost shall be determined according to the estimated value according to the project budget, cost or actual cost of the project shall be determined from the date of reaching the intended usable state, and depreciation shall be accrued, and the original provisional value shall be adjusted according to the actual cost after the final accounts of completion shall be handled, but the depreciation amount that has been accrued shall not be adjusted.

The new production line as a whole will be transferred to fixed assets after passing the test run and producing qualified products (that is, after obtaining the production acceptance notice). If a single equipment is part of the overall production line, it needs to be included in the fixed assets after the entire production line reaches the state of use, and before that, if the equipment that needs to be installed is included in the construction in progress, the equipment that does not need to be installed is included in the engineering materials.

The specific reasons for the postponement of the diphtheria-pertussis project are as follows:

As of December 31, 2024, the diphtheria-tetanus-pertussis project has completed all workshop construction works such as civil engineering and purification

and has completed equipment commissioning, verification and other related work.

In December 2024, six departments, including the National Bureau of Disease Control and Prevention, jointly issued the "National Immunization Regulations".

Notice on the adjustment of the immunization schedule of diphtheria-tetanus-tetanus-tetanus-tetanus-pertussis vaccine", which adjusts the immunization schedule of pertussis-diphtheria-tetanus combined vaccine, which is administered at the original age of 3, 4, 5 and 18 months

1 dose of diphtheria-pertussis (DTP) vaccine and 1 dose of diphtheria-pertussis (DT) vaccine at 6 years of age are adjusted to 2, 4, 6, 18 months

1 dose of diphtheria-pertussis (DTP) vaccine at age and 6 years of age, starting January 1, 2025.

Combined with the changes in the immunization schedule of the vaccine, the company has made corresponding adjustments to the clinical protocol of the diphtheria-pertussis vaccine (three-component) under development, resulting in a delay in the research progress of the project.

At present, the company's diphtheria-pertussis vaccine (three components) has completed the preparation of phase III clinical samples, and plans to carry out phase III clinical trial enrollment in 2025, and will evaluate the immunogenicity and safety according to the new immunization schedule. It is expected that it will take about 24-36 months to obtain the clinical study summary report and submit the manufacturing registration application, and reach the expected usable status specified in the company's accounting policies after obtaining the notice of acceptance of the product production registration application.

In summary, combined with factors such as the registration approval of the company's diphtheria-pertussis vaccine (three-component) and the progress of clinical trials, the date when the diphtheria-pertussis project reaches the intended usable state is adjusted to April 2028.

Fourth, the impact of the postponement of the diphtheria-pertussis project on the company

The adjustment of the time for the investment project of the raised funds to reach the predetermined usable state is a prudent decision made by the company based on the actual progress of the relevant fundraising and investment projects and the corresponding varieties, and only involves the change of the time when the fundraising and investment projects reach the predetermined usable state, and does not involve the change of the implementation subject, implementation method and total investment amount of the fundraising and investment project, and will not

It has a substantial impact on the implementation of fundraising and investment projects. The postponement of the diphtheria-tetanus-pertussis project will not have a substantial impact on the implemented project, and match the company's production and operation conditions at this stage, there is no disguised change in the investment direction of raised funds and damage to the interests of shareholders, in line with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange on the management of funds raised by listed companies, will not adversely affect the normal operation of the company, there is no damage to the interests of shareholders, and is in line with the company's long-term development plan and the long-term interests of shareholders.

5. Explanation of the review procedures and special opinions on performance

On April 17, 2025, the company held the fifth meeting of the sixth board of directors and the second meeting of the sixth board of supervisors

At the meeting, the "Proposal on the Extension of Some Fund-raising Projects" was deliberated and passed, and it was agreed to adjust the time for the diphtheria-tetanus-pertussis project to reach the intended usable state to April 2028. The sponsor, CITIC Securities Co., Ltd., issued a clear verification opinion. This matter does not need to be submitted to the shareholders' meeting of the company for deliberation.

(1) Opinions of the Board of Supervisors

The Board of Supervisors believes that the postponement of the diphtheria-tetanus-pertussis project is a prudent decision made by the company based on the actual situation of the project implementation, and the project postponement does not change the investment content, total investment amount and implementation subject of the fund-raising project, and will not have a substantial impact on the implementation of the fund-raising project. The decision-making and approval procedures of this matter are in accordance with relevant laws and regulations and the provisions of the Company's "Management System for Raised Funds". The postponement of some fund-raising projects does not change the investment direction of the raised funds in disguise and damage the interests of shareholders, and there is no illegal use of the raised funds, which will not adversely affect the normal operation of the company. Therefore, we unanimously agreed to the postponement of the company's diphtheria-pertussis project.

(2) The verification opinions of the sponsor institution

The sponsor believes that the postponement of part of the company's initial public offering of shares has been approved by the company

The fifth meeting of the sixth session of the Board of Directors and the second meeting of the sixth session of the Board of Supervisors will be held on April 17, 2025

reviewed and fulfilled the necessary approval procedures, and met the requirements of the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing, Regulatory Guidelines for Listed Companies No. 2 - Regulatory Requirements for the Management and Use of Funds Raised by Listed Companies (Revised in 2022), Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operation, Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange, Measures for the Continuous Supervision of Listed Companies on the Science and Technology Innovation Board (Trial) and other relevant regulations. The postponement of part of the company's initial public offering is a prudent decision made based on the actual situation of the implementation of the project, and there is no change or disguised change in the investment direction of the raised funds and damage to the interests of shareholders.

To sum up, the sponsor has no objection to the postponement of part of the fundraising project of Baike Biotech.

The announcement is hereby made.

Board of Directors of Changchun Baike Biotechnology Co., Ltd

April 21, 2025